Sanofi CEO Paul Hud­son dives deep­er in­to mR­NA, buy­ing out an un­der-the-radar Fred Hutch spin­out

Sanofi CEO Paul Hud­son may not be ful­ly on board with the mR­NA rev­o­lu­tion, but he ev­i­dent­ly still be­lieves in the tech­nol­o­gy’s po­ten­tial.

On Fri­day af­ter­noon, Sanofi an­nounced that they bought out the lit­tle-known mR­NA biotech Tidal Ther­a­peu­tics, hop­ing to lever­age their tech­nol­o­gy to treat can­cer and im­muno­log­i­cal dis­or­ders. Spun out of the Fred Hutch in­sti­tute in 2019 and seed­ed at Cam­bridge’s Lab­Cen­tral, the young com­pa­ny will now re­ceive $160 mil­lion in cash and $310 mil­lion in po­ten­tial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER